{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Intensity Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"INTS"},"Address":{"label":"Address","value":"1 ENTERPRISE DRIVE,SUITE 430 SUITE 430, SHELTON, Connecticut, 06484, United States"},"Phone":{"label":"Phone","value":"203-221-7381"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725)."},"CompanyUrl":{"label":"Company Url","value":"https://www.intensitytherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brian D. Schwartz","title":"Executive VP-Clinical Development"},{"name":"Lewis H. Bender","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}